Table 1. Frequency of demographic and clinical characteristics of 70 NSCLC patients.
| Characteristics | Number of patients (n=70) |
|---|---|
| Age, median (range) in years | 78 (41-96) |
| ≤77 years | 32 (45.7%) |
| >77 years | 33 (47.1%) |
| Gender | |
| Male | 44 (62.9%) |
| Female | 21 (30.0%) |
| Ancestry | |
| European | 48 (68.6%) |
| Asian | 2 (2.9%) |
| African | 2 (2.9%) |
| Smoking status | |
| Smoker | 21 (30.0%) |
| Non-smoker | 7 (10.0%) |
| Histological subtype | |
| Adenocarcinoma | 46 (65.71%) |
| Squamous cell carcinoma | 24 (34.3%) |
| Pathological TNM stage# | |
| IA | 14 (20.0%) |
| IB | 10 (14.3%) |
| IIA | 10 (14.3%) |
| IIB | 13 (18.6%) |
| IIIA | 11 (15.7%) |
| Relapse | |
| No | 13 (18.6%) |
| Local-regional | 11 (15.7%) |
| Distant metastasis | 12 (17.4%) |
| Post-operative treatment | |
| Chemotherapy (platinum-based) | 23 (32.8%) |
| Radiotherapy | 4 (4.3%) |
| Chemoradiotherapy | 6 (8.6%) |
| Tyrosine kinase inhibitor (erlotinib) | 2 (2.9%) |
| Status for overall survival | |
| Live | 23 (32.9%) |
| Dead | 38 (54.3%) |
| Follow-up, median (range) in months | 49 (0-175) |
| EGFR status | |
| Mutation exons 18-21 | 14 (20.0%) |
| Uncommon mutation exons 3, 7, 14, 16, 22, 27, 28 | 9 (12.9%) |
| Wild type | 47 (67.1%) |
NSCLC: non-small cell lung cancer. Some cases lacked follow-up information: age (5); gender (5); ancestry (18); smoking status (42); TNM stage (12); relapse (34); and survival status (9). #International Association for the Study of Lung Cancer (8th edition).